Clinical trials: Vehicle, completed
Bacterial Conjunctivitis
Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
To evaluate the clinical and microbial efficacy of ISV-403 administered three times a day (TID) for 5 days compared to vehicle three times a day for 5 days in the treatment of bacterial conjunctivitis
- Trial name
- NCT00622908
- Testing
- ISV-403, Vehicle
- Volunteers
- 270 people
- Sponsor
- Bausch & Lomb Incorporated
Seasonal Allergic Rhinitis
Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)
The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to <12 years old who have seasonal allergic rhinitis.
- Trial name
- NCT01915823
- Testing
- azelastine hydrochloride and fluticasone propionate, Dymista vehicle
- Where
- 31 sites in United States
- Volunteers
- 348 people
- Sponsor
- Meda Pharmaceuticals
Hard to Heal Wounds, Venous Leg Ulcers
Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds
The main objective of this study is to assess the safety and the efficacy of EscharEx in preparing the wound's bed in patients with hard to heal venous leg ulcers, diabetic lower extremity ulcers and traumatic/post operative…
- Conditions
- Hard to Heal Wounds, Venous Leg Ulcers, Diabetic Lower Extremity Ulcers, Traumatic/ Post Operative Wounds
- Trial name
- NCT02020746
- Testing
- EscharEx, Gel Vehicle
- Where
- 8 sites in Israel
- Volunteers
- 111 people
- Sponsor
- MediWound Ltd
Plaque Psoriasis
Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients
This study is to evaluate the efficacy and safety of M518101 and the dose relationship among two doses of M518101 and placebo in male and female plaque psoriasis patients.
- Trial name
- NCT01301157
- Testing
- M518101, Dovonex
- Where
- 32 sites in United States
- Volunteers
- 294 people
- Sponsor
- Maruho Co., Ltd.
Hypovolemic Shock, Blood Loss
PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock
This is a prospective, multi-centric, randomized, double-blind, parallel, controlled phase-II efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock. Centhaquine is highly safe and well tolerated.
- Trial name
- NCT04056065
- Testing
- Normal Saline, Centhaquine
- Where
- 7 sites in India
- Volunteers
- 50 people
- Sponsor
- Pharmazz, Inc.
Adenoviral Conjunctivitis
Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis
The purpose of this study is to evaluate the clinical and microbiological efficacy and safety of NVC-422 compared to vehicle for adenoviral conjunctivitis.
- Trial name
- BAYnovation™ (NCT01532336)
- Testing
- NVC-422 Solution, 0.3%, NVC-422 Vehicle Solution
- Where
- 58 sites in United States, Brazil and 2 more
- Volunteers
- 500 people
- Sponsor
- NovaBay Pharmaceuticals, Inc.
Psoriasis Vulgaris
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.
To assess safety, tolerability and pharmacodynamics effect of treatment with microarray patches containing calcipotriol and betamethasone dipropionate.
- Trial name
- NCT03898583
- Testing
- Microarray patch A, Microarray patch B, Daivobet
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- LEO Pharma
Healthy Volunteers
A Study to Investigate the Effects of Cortexolone 17α-propionate (and Its Metabolites) on Healthy Volunteers' Heart
This is a randomised, double blind placebo controlled Phase I study which will assess the safety, tolerability and PK of Cortexolone 17α-propionate (and its metabolites), and its effects on the QTc interval when administered as…
- Trial name
- NCT03665194
- Testing
- Cortexolone 17α-propionate solution
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Cassiopea SpA
Acne Vulgaris
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil Gel compared to vehicle in patients with acne vulgaris
- Trial name
- NCT03073486
- Testing
- Olumacostat Glasaretil Gel, 5.0%, Olumacostat Glasaretil Gel, Vehicle
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 744 people
- Sponsor
- Dermira, Inc.
Open-angle Glaucoma, Ocular Hypertension
Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)
This study was to compare the safety and efficacy of the preservative-free formulation of 0.0015% MK2452 (tafluprost) and preservative-free 0.5% timolol maleate in patients with open-angle glaucoma and ocular hypertension.
- Trial name
- NCT01026831
- Testing
- Preservative-Free Tafluprost, Comparator: timolol
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
Impetigo
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
This is a Phase 2 study evaluating the safety, tolerability, systemic exposure, and activity of topical ATx201 GEL (2% and 4%) treatment for 1, 2, or 5 days in outpatients with primary nonbullous or bullous impetigo.
- Trial name
- NCT03429595
- Testing
- ATx201, ATx201 GEL Vehicle
- Where
- 16 sites in South Africa
- Volunteers
- 210 people
- Sponsor
- UNION therapeutics
Tinea Pedis
A Therapeutic Equivalence Study of Ketoconazole Cream 2%
Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis.
- Trial name
- NCT04203342
- Testing
- Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)
- Where
- 3 sites in United States, Belize
- Volunteers
- 682 people
- Sponsor
- Douglas Pharmaceuticals America Ltd
Dry Eye Disease, Sjögren Syndrome
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
This study will examine the efficacy and safety of tivanisiran sodium eye drops versus vehicle after a 2-week run-in phase when dosed once daily for 3 months in subjects with signs and symptoms of dry eye disease (DED) due to…
- Trial name
- NCT04819269
- Testing
- Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
- Where
- 46 sites in United States, Spain
- Volunteers
- 203 people
- Sponsor
- Sylentis, S.A.
HIV Infections
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)
The aim of this study was to determine if virologically suppressed, human immunodeficiency virus type 1 (HIV-1) infected adults on an antiretroviral regimen (including 2 nucleoside reverse transcriptase inhibitors [NRTIs] plus a…
- Trial name
- NCT02422797
- Testing
- DTG 50 mg, RPV 25 mg, CAR
- Where
- 61 sites in United States, Argentina and 9 more
- Volunteers
- 518 people
- Sponsor
- ViiV Healthcare
Plaque Psoriasis
A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis
This Phase 3 study (Study 305) has been designed to determine and compare the efficacy and safety of 188-0551 Spray and Vehicle Spray applied twice daily for up to four weeks in subjects with plaque psoriasis.
- Trial name
- 305 (NCT03759197)
- Testing
- 188-0551 Spray, Vehicle Spray
- Where
- 12 sites in United States
- Volunteers
- 206 people
- Sponsor
- Therapeutics, Inc.
Presbyopia
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
Safety and efficacy of POS in participants with presbyopia
- Trial name
- VEGA-3 (NCT06542497)
- Testing
- 0.75% phentolamine ophthalmic solution
- Where
- 39 sites in United States
- Volunteers
- 569 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Atopic Dermatitis
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.
- Trial name
- NCT01228513
- Testing
- ZK245186
- Where
- 16 sites in United States, Japan
- Volunteers
- 263 people
- Sponsor
- Bayer
Norovirus
Recombinant, Bivalent, Norovirus Vaccine Study
This clinical study will evaluate the vaccine candidate rNV-2v, which is under development to prevent disease triggered by noroviruses. Noroviruses are one of the leading causes of gastrointestinal diseases in the world.
- Trial name
- NCT05508178
- Testing
- Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg), Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Icon Genetics GmbH
Atopic Dermatitis
Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1% OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.
- Trial name
- NCT03018691
- Testing
- OPA-15406
- Where
- 4 sites in Japan
- Volunteers
- 73 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Usual Type Vulval Intraepithelial Neoplasia (uVIN)
Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN
To assess the pharmacodynamics, safety/tolerability and efficacy of topical Omiganan (CLS001) in patients with usual type vulvar intraepithelial neoplasia (uVIN).
- Trial name
- NCT02596074
- Testing
- Omiganan (CLS001) topical gel, Vehicle topical gel
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Maruho Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.